Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6100686 | Journal of Crohn's and Colitis | 2010 | 5 Pages |
Abstract
Adalimumab has shown its efficacy in our paediatric CD patients naïve to other anti-TNF α drugs. Early introduction of anti-TNF α antibodies in these patients could help to a better control of the disease. Its less immunogenicity and the possibility of a home-based administration are advantages when compared to other parenteral anti-TNF treatments. Change to monotherapy after prior successful combination therapy with azathioprine and adalimumab is a safe strategy that can help to minimize possible risks of intensive immunomodulation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
J. MartÃn-de-Carpi, N. Pociello, V. Varea,